Chicago, Illinois (PRWEB) August 01, 2014
As AndroGel lawsuits and testosterone lawsuits continue to be filed across the country, Ronald E. Johnson, Jr. has been appointed as co-lead counsel to represent the men injured by AndroGel and other testosterone medications. Since the Fall of 2013, Ron and his firm, Schachter, Hendy & Johnson, P.S.C. have worked diligently to investigate and prosecute the claims of men who suffered heart attacks, strokes, pulmonary embolisms, and blood clots as a result of taking testosterone. As a result of these efforts, the medical community and public are being made aware of the true risks of taking testosterone.
In January 2014, the U.S. Food and Drug Administration (FDA) announced that it was investigating the safety of testosterone medications and their potential relationship to heart attacks and strokes (http://www.fda.gov/Drugs/DrugSafety/ucm383904.htm). The FDA will hold a conference in September 2014 to address these issues.
The labeling for all testosterone medications was changed and broadened by the FDA on June 19, 2014 concerning the risks of blood clots (http://www.fda.gov/drugs/drugsafety/ucm401746.htm). Prior labeling only warned about blood clots in the legs as a result of polycythemia. The new labeling warns about blood clots in the legs and lungs generally and not as related to any specific condition other than testosterone use.
Lawsuits filed across the nation are being coordinated in a multi-district litigation (In Re: Testosterone Replacement Therapy Products Liability Litigation, 1:14-cv-01748) before Judge Matthew Kennelly in the Northern District of Illinois. As co-lead counsel for all plaintiffs in testosterone lawsuits, Ron will continue to fight for justice for the men and families whose lives have been devastated by the use of testosterone medications.